• Behavioral Health
  • Clinical Insights
  • Treatment

August 2023 drug trend report

Aug 2nd, 2023

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market.

Brand name drug launches*

Uzedy

  • Indicated for: Treatment of schizophrenia in adults.
  • Dosage form: Extended-release injectable suspension.
  • Status: Available now.

Abilify Asimtuffii

  • Indicated for: Treatment of schizophrenia in adults and as a maintenance monotherapy treatment of bipolar I disorder in adults.
  • Dosage form: Long-acting injectable.
  • Status: Available now.

Brixadi

  • Indicated for: Treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
  • Dosage form: Extended-release injectable.
  • Status: Expected September of 2023 (Genoa is working to become a REMS-certified pharmacy to dispense Brixadi).

Generic drug launches*

Vyvanse capsules and chewable tablets (Lisdexamfetamine Dimesylate)

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older.
  • Status: Expected August 25, 2023.

Current drug shortages*

Brand:

Adderall

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) and/or narcolepsy.
  • Status: Estimated recovery December 2023.

Mounjaro

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Ozempic

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Generic:

Lorazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Estimated recovery August 2023

Clonazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Recovery TBD.

Divalproex DR 500mg

  • Indicated for: Treatment of bipolar disorder, migraines, and other indications.
  • Status: Recovery TBD.

*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.

Recent Posts


  • 340B
Your questions, answered: 340B manufacturer pricing restrictions

Drug manufacturers began implementing restrictions for 340B pricing in 2020, citing alleged misuse by safety-net providers and explosive growth of the 340B Drug Pricing Program. Since then, restrictions for the...

  • Behavioral Health
  • Clinical Insights
  • Treatment
Currently available and emerging therapy options for treatment-resistant depression

Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...

  • Art Celebration
  • Consumer Stories
  • People-first Pharmacy Care
Genoa Art Celebration participant heals through art, helps others after losing daughter to substance use disorder

Content warning: This post discusses mental illness and substance use. Please call the Suicide and Crisis Lifeline at 988, the Substance Abuse and Mental Health Services Administration’s National Helpline at...

  • Consumer Stories
  • Partnering with Genoa
  • People-first Pharmacy Care
Genoa pharmacist turned director reunites with consumer

When Jeannie Barrett, PharmD, transitioned from her role as a pharmacist to director of pharmacy operations for Genoa Healthcare, she wondered if she’d get the chance to see her consumers...